DRDO’s Covid Drug: 2-DG Commercially Launched By Dr. Reddy’s Labs: MRP Fixed At Rs 990

The drug is to be consumed orally and will be sold in single sachets.

Dr Reddy’s is launching 2-Deoxy-D-Glucose (2-DG) , a drug used for Covid treatment which helps expedite recovery and reduces the need for oxygen.

The drug is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in partnership with Dr Reddy’s Laboratories.

Initial Phase Of Commercial Launch

The drug’s commercial launch will be available only for hospitals in metros and Tier 1 cities initially.

The pharmaceutical firm stated that it will first supply the drug to major govt and private hospitals throughout the country in the initial phase.

It will later expand availability to the rest of India.

The price limit has been set at Rs 990 and govt hospitals will receive it at a discounted rate.

How It Will Work

The drug is to be consumed orally and will be sold in single sachets.

It can be administered only if a doctor prescribes it for a patient.

The administration of the drug will be supervised by a qualified physician and only those hospitalised for moderate or severe symptoms will be eligible to receive it.

The patient, in this case, will receive the drug as an additional therapy to the main treatment plan.

Vaccine Still Required

2-DG got approval for emergency use on May 1.

Dr Reddy’s stated that it is pleased with its partnership with DRDO in producing the drug which adds to the pharmaceutical’s portfolio of drugs which help in the treatment of moderate to severe conditions.

However, patients will also require a vaccine to beat the disease.

If Your Employees Are Not Vaccinated, Your Business Will Shut Down In This State!

Comments are closed, but trackbacks and pingbacks are open.

who's online